FORMULATION AND EVALUATION OF SUBLINGUAL TABLETS OF TERAZOSIN HYDRO-CHLORIDE

The objective of the current study was to develop and optimize sublingual tablets of Terazosin Hydrochloride, which is an effective drug in the treatment of Benign Prostate Hyperplasia, Hypertension. Sublingual tablets of Terazosin Hydrochloride were prepared by direct compression method using different superdisintegrating agents such as Crosspovidone, Sodium starch glycolate and Crosscarmellose sodium. The tablets were evaluated for pre-compression studies like Bulk density, Tapped density, Carr’s index, Hausner’s ratio and post-compression studies like Thickness, Hardness, Weight variation, Friability, drug content, Wetting time, Water absorption ratio, in-vitro disintegration time, in-vitro dispersion time,  in-vitro dissolution study and also drug  release kinetic study. The Hardness, Weight variation, Thickness, Friability and Drug content of tablets were found to be acceptable according to pharmacopoeial limits. An optimized formulation i.e. F6 was found, which provided short wetting time of 67sec, water absorption ratio of  39.01 , in-vitro disintegration time of 61sec and in-vitro dispersion time of 112sec. From the above results It indicated that the amount of superdisintegrant i.e. Crosspovidone was significantly affected the dependent variables like Wetting time, Water absorption ratio, in-vitro disintegration time and in-vitro dispersion time. The best in-vitro drug release was found to be in formulation F6 i.e. 102% during the end of 15min. The in-vitro drug release data of all Terazosin Hydrochloride tablets were subjected to goodness of fit test by linear regression analysis according to Zero order reaction, 1st order equation, Higuchi’s equation and Korsemeyer-Peppas equation to ascertain the mechanism of drug release. Hence the drug release followed the first order release kinetics with diffusion mechanism.